fin.cloudexit.ch
Biotech catalyst trading · compact research page · live starting set

Three names. One catalyst lens.

This page starts your fin.cloudexit.ch biotech watchlist with INMB, BDMD, and UNCY. It is built for event-driven research rather than long-form valuation work: what the company is, where the regulatory angle sits, what could move the stock next, and where to check the FDA trail quickly.

3 tickersINMB, BDMD, and UNCY as the first tracked set
FDA path includedplain-English explanation of Phase 1, 2, 3 and approval flow
Source-firstbuilt around TradingView/company descriptions plus official FDA resources
fin.cloudexit.ch / catalyst shell
$watchlist --add INMB BDMD UNCY
›INMB: neuroscience + cancer pipeline, small-cap event sensitivity
›BDMD: currently a healthcare/med-tech ticker, not classic biotech
›UNCY: oxylanthanum carbonate under FDA review is the key near-term angle
Starter watchlist

INMB, BDMD, and UNCY under one event-driven framework.

These are not equal setups. INMB and UNCY fit a classic biotech catalyst lens more naturally, while BDMD currently looks more like a broader healthcare/medical-technology name and should be treated accordingly.

NASDAQ: INMB

INmune Bio

Small-cap biotech focused on Alzheimer’s disease and an oncology/immunology pipeline.

$1.45 -1.38%
Market cap: $38.5M Volume: 241,102 Pipeline: XPro1595 / CORDStrom / INKmune

INmune Bio’s current pipeline is centered on three platforms: XPro1595 in early Alzheimer’s disease, CORDStrom in recessive dystrophic epidermolysis bullosa (RDEB), and INKmune in cancer. In May 2026 the company said XPro1595 had FDA Fast Track designation and FDA alignment on a seamless Phase 2b/3 registrational path in biomarker-enriched early Alzheimer’s patients.

  • XPro1595: next watchpoints are final Phase 2b/3 protocol submission, management timing updates, and additional MINDFuL imaging analyses that the company said are expected in the near future.
  • CORDStrom: company guidance points to a UK MHRA filing in mid-summer 2026, an EMA filing shortly after, and an FDA BLA submission expected in Q4 2026.
  • INKmune: ongoing Phase 1/2 work in metastatic castration-resistant prostate cancer; watch for enrollment or data updates rather than a near-term approval event.
NASDAQ: BDMD

Baird Medical Investment Holdings Ltd

Healthcare/medical-technology exposure rather than a clean development-stage biotech profile.

$1.63 -3.07%
Market cap: $66.8M Volume: 78,001 Device pipeline: MWA platform, not drug pipeline

BDMD is better framed as a med-tech and regulatory-expansion story than as a drug-development name. Public materials describe a microwave ablation platform plus related devices, with current focus on thyroid and liver indications and additional expansion targets under review.

  • Current platform: microwave ablation therapeutic apparatus, microwave ablation needles, and a single-use sterile biopsy needle; this is not a classic molecule/Phase 2/Phase 3 biotech setup.
  • Pipeline expansion: the 2024 annual report says the company is pursuing Class III indication expansion covering breast lumps, pulmonary nodules, varicose veins, bone tumors, and uterine fibroids, with those indications expected by 2026.
  • Next watchpoints: regulatory-clearance announcements, U.S. commercial-ramp updates, and conference/physician-adoption signals rather than a drug-style PDUFA or trial readout.
NASDAQ: UNCY

Unicycive Therapeutics

Biotech with a visible FDA angle centered on oxylanthanum carbonate.

$7.22 -12.62%
Market cap: $215.7M Volume: 955,938 Pipeline: OLC / UNI-494

Unicycive’s pipeline is straightforward: oxylanthanum carbonate (OLC) for hyperphosphatemia in CKD patients on dialysis, and UNI-494 for acute-kidney-injury-related conditions including delayed graft function. OLC remains the near-term value driver because it is already under FDA review.

  • OLC: FDA review of the NDA resubmission is on track, and the company’s May 2026 update gives a PDUFA target action date of June 29, 2026.
  • If approved, management says commercial-readiness work is already underway with potential launch planning for later in 2026.
  • UNI-494: orphan-drug designated for prevention of delayed graft function in kidney transplant patients and has completed a Phase 1 dose-ranging safety study; the next event to watch is company guidance on the next clinical step.
Trading framework

How catalyst trading usually works in biotech.

In small and mid-cap biotech, the market often reprices the company around a single event. The setup is less about steady cash-flow modeling and more about what happens before, during, and after a catalyst.

Typical catalyst buckets

  • topline clinical data
  • dose-escalation or cohort updates
  • FDA filing acceptance or review updates
  • advisory committee meetings or label decisions
  • conference presentations and investigator meetings
  • partnerships, financing, or restructuring

What usually matters most

  • how important the event is relative to the company’s size
  • whether the event is binary or just incremental
  • how much dilution risk exists before the event lands
  • whether the run-up is already crowded before the news
  • whether you want a pre-event trade, an event hold, or only a post-event reaction plan
FDA process

What Phase 1, 2, and 3 usually mean in plain English.

The exact path varies by drug, biologic, device, and rare-disease program, but the broad flow is similar enough that traders can use it as a map for where the next catalyst may appear.

1

Preclinical + IND

Before human testing, the company builds lab and animal evidence, manufacturing plans, and safety materials. If the FDA allows the IND to proceed, human trials can begin.

2

Phase 1

Usually a first-in-human safety step. The main question is not “does this make billions?” but “can this be dosed safely and what does the early PK/PD profile look like?”

3

Phase 2

This is where investors often start caring more aggressively about proof-of-concept. The company is trying to show a real efficacy signal, an appropriate dose, and enough evidence to justify a larger pivotal study.

4

Phase 3 + filing

Usually the pivotal or confirmatory stage. If results are strong enough, the company files an NDA or BLA. After review, the outcome can be approval, delay, label limitation, or rejection/complete response.

How the process often feels to traders

  • Phase 1 can move a micro-cap sharply, but it is often still early and fragile.
  • Phase 2 is frequently where expectation and volatility expand fast.
  • Phase 3 and approval events can be the most binary because the market expects clearer answers.
  • Regulatory review can be as important as the science: filing acceptance, review delays, and label scope all matter.

What “approved” actually means

  • It does not always mean unlimited commercial upside.
  • Approval can come with narrow labels, warnings, post-marketing obligations, or slower-than-expected launch dynamics.
  • Sometimes the stock sells off on approval because expectations were already too high before the event.
FDA approval list

Where to check approvals and regulatory status quickly.

If you want an actual approval list rather than commentary, these are the first FDA resources worth keeping open. They are more useful than random summaries because they anchor you to the primary source.

Approval-list style resources

  • 2026 biological license application approvals — useful for biologics-specific approvals.
  • For each watched company, pair the FDA pages with the company IR site and SEC filings so you can confirm whether a program is still in review, approved, delayed, or resubmitted.
  • Practical workflow: company PR → SEC filing → official FDA page/database → only then build the trade view.
Notes

Important context for this first version.

This page is a compact starter, not a complete biotech data room. It is designed to help you decide which names deserve deeper work next.

Why BDMD is flagged differently

BDMD currently resolves to Baird Medical Investment Holdings Ltd in the live market data source used here. That makes it different from INMB and UNCY. It may still belong in the broader healthcare watchlist, but it should not automatically inherit the same trial-phase logic.

Suggested next expansion

The next useful upgrade would be a per-ticker section for: latest company press release, next known catalyst date, financing/cash risk, and a clean “pre-event / hold / post-event” trade plan.